Stories about Diabetes

Subscribe to Diabetes

05.11.2021 – 13:47

Novo Nordisk A/S
Wegovy(TM) Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity

Bagsværd, Denmark (ots/PRNewswire) - - The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy(TM) at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo - The trial also showed that 77.1% of study participants who received Wegovy(TM) lost at ...

more
02.11.2021 – 09:01

The International Diabetes Federation (IDF)
Diabetes is "a pandemic of unprecedented magnitude" now affecting one in 10 adults worldwide, reveals the International Diabetes Federation

Brussels (ots/PRNewswire) - New figures from the International Diabetes Federation reveal that 537 million adults around the globe are living with diabetes The International Diabetes Federation (IDF) has released new figures showing that 537 million adults are now living with diabetes worldwide - a rise of 16% (74 ...

more
28.10.2021 – 07:00

Roche Diabetes Care
Roche and the Zur Rose Group announce collaboration to offer innovative health journeys for people living with diabetes

Basel, Switzerland (ots/PRNewswire) - - Roche, a world leader in integrated Personalised Diabetes Management, and the Zur Rose Group, provider of a European digital healthcare ecosystem, announce their collaboration to improve everyday therapy management and better address the needs of 60 million people living with ...

more
28.10.2021 – 07:00

Roche Diabetes Care
Roche and the Zur Rose Group announce collaboration to offer innovative health journeys for people living with diabetes

Basel (ots) - - Roche, a world leader in integrated Personalised Diabetes Management, and the Zur Rose Group, provider of a European digital healthcare ecosystem, announce their collaboration to improve everyday therapy management and better address the needs of 60 million people living with diabetes in Europe [1] - ...

more
13.07.2021 – 15:13

News Direct

ZOE Study Reveals Eating a Plant Rich Diet Reduces Risk of Developing COVID-19 and Going to the Hospital

more
19.05.2021 – 07:00

Roche Diabetes Care
Roche launches mySugr Pump Control within the mySugr app to simplify insulin pump therapy via smartphone

Basel (ots) - ● mySugr now allows control of the Accu-Chek Insight insulin pump directly via smartphone, starting in Austria, bringing more discretion and simplicity to the life of people with diabetes. ● With the mySugr Pump Control, people with diabetes can deliver standard bolus and view pump status in the ...

more
06.05.2021 – 13:36

Roche Diabetes Care
Roche collaborates with Lilly to support people with diabetes on insulin pen therapy

Basel (ots) - ● Roche and Lilly will integrate data from Lilly’s connected insulin pen solution into the mySugr app in several countries. ● Both companies are dedicated to driving new possibilities to ease the complexity of daily decision making for people with diabetes on insulin pen therapy and their healthcare professionals. ● By collaborating with Lilly, ...

more
01.04.2021 – 07:46

DocMorris Adipositas Care
Introducing DocMorris Adipositas Care (Obesity Care), a digital hub empowering people with obesity to find relevant care for a better quality of life

Berlin (ots) - The Novo Nordisk and Zur Rose Group collaboration presents DocMorris Adipositas Care, a digital hub which provides people living with obesity a new way to find the right care. Adipositas Care thoughtfully empowers people living with obesity by enabling them to learn about obesity and discover possible ...

more
26.03.2021 – 14:23

Novo Nordisk A/S
Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years

Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12-17 years.1 Over the last 20 years, the ...

more
23.03.2021 – 20:46

Novo Nordisk A/S
Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial

Bagsværd, Denmark (ots/PRNewswire) - Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention. New results from the STEP phase 3a clinical trial programme demonstrated weight loss ...

more
11.12.2020 – 13:08

Roche Diabetes Care
Roche teams up with Diabeloop to advance the management of insulin pump therapy

Basel (ots/PRNewswire) - - The partnership will create new opportunities to lower the burden for people with diabetes in daily therapy management and to improve therapy outcomes1. - By partnering with Diabeloop, Roche steps into the field of automated insulin delivery (AID) representing a milestone in Roche's strategy of integrated Personalised Diabetes Management ...

more
11.12.2020 – 07:00

Roche Diabetes Care
Roche teams up with Diabeloop to advance the management of insulin pump therapy

Basel (ots) - - The partnership will create new opportunities to lower the burden for people with diabetes in daily therapy management and to improve therapy outcomes(1). - By partnering with Diabeloop, Roche steps into the field of automated insulin delivery (AID) representing a milestone in Roche's strategy of integrated Personalised Diabetes Management (iPDM). Roche ...

more
01.12.2020 – 09:12

Grünenthal Group
Grünenthal agrees to acquire European rights to CRESTOR [TM] (rosuvastatin) from AstraZeneca

Aachen, Germany (ots) - Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced that it has agreed to acquire the European rights (excluding Spain and the UK) to CRESTOR[TM] (rosuvastatin) and its associated brands for a total consideration of up to US$ 350 million. CRESTOR(TM) is among the leading statin products in Europe and is ...

more
13.11.2020 – 08:00

ForaCare Suisse AG

FORA® 6 Blood Glucose Monitors Help Diabetic Patients Monitor COVID-19 Risks

more
21.07.2020 – 16:00

Grünenthal Group
Grünenthal and Averitas Pharma Announce U.S. FDA Approval of QUTENZA® for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy of the Feet

Aachen, Germany & Morristown, N.J. (ots) - - Neuropathic pain associated with diabetic peripheral neuropathy is a progressive and debilitating complication of diabetes that will affect approximately more than 5 million Americans in 20201. - QUTENZA® is the first and only topical, non-systemic, non-opioid pain ...

more
27.04.2020 – 17:22

Helmholtz Zentrum München

2
Beta cells from stem cells: Potential for cell replacement therapy

Read the study

more
31.03.2020 – 18:00

Novo Nordisk A/S
Saxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity

Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda® (liraglutide 3.0 mg) in adolescents (aged ...

more
09.01.2020 – 09:03

Technische Universität München
Gene network helps to turn white fat into beneficial calorie burning fat

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/ High resolution images: https://mediatum.ub.tum.de/1524726 NEWS RELEASE A new approach to treating overweight and obesity Gene network helps to turn white fat into beneficial calorie ...

more
18.12.2019 – 14:07

Grünenthal Group
Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

Morristown, N.J. (ots) - · PDUFA date set for July 19, 2020 · If approved, QUTENZA would be the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the ...

more

1